New Delhi: The Serum Institute of India gets approval for the enrollment of children between the ages of seven and 11 in the clinical trial of US drugmaker Novavox’s covid-19 vaccine. Central Drug Standards Control Organization (CDSCO) given the permission.
The vaccine, which is an Indian-made version of the nova vaccine shot, is being tested in people ages 12–17. The drug company has presented safety data for the first 100 people who participated in the experiment.
The Novavax vaccine has not yet been approved in India. Earlier this month, Adar Poonavalla, head of the Serum Institute, said he hoped to approve giving Novavax to people under the age of 18 in January or February next year. The Covshield vaccine, developed by the Serum Institute, is widely used in the country for the vaccination of adults.
In the case of children, only the DNA Covid-19 vaccine of Zydus Cadillac was approved. The vaccine is approved for immediate use in people aged 12–18 years.
